Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MOR |
---|---|---|
09:32 ET | 22265 | 6.42 |
09:33 ET | 6194 | 6.44 |
09:35 ET | 3220 | 6.435 |
09:37 ET | 11610 | 6.48 |
09:39 ET | 12013 | 6.43 |
09:42 ET | 6330 | 6.425 |
09:44 ET | 24798 | 6.43 |
09:46 ET | 1202 | 6.44 |
09:48 ET | 14892 | 6.42 |
09:50 ET | 9330 | 6.43 |
09:51 ET | 6984 | 6.38 |
09:53 ET | 23142 | 6.295 |
09:55 ET | 16308 | 6.2998 |
09:57 ET | 2944 | 6.35 |
10:00 ET | 3619 | 6.35 |
10:02 ET | 800 | 6.4 |
10:04 ET | 650 | 6.38 |
10:06 ET | 2134 | 6.39 |
10:08 ET | 800 | 6.41 |
10:09 ET | 9200 | 6.44 |
10:11 ET | 1547 | 6.43 |
10:13 ET | 3063 | 6.45 |
10:15 ET | 4065 | 6.46 |
10:18 ET | 3200 | 6.525 |
10:20 ET | 7968 | 6.5016 |
10:22 ET | 11509 | 6.51 |
10:24 ET | 1288 | 6.48 |
10:26 ET | 8874 | 6.49 |
10:27 ET | 6852 | 6.53 |
10:29 ET | 14815 | 6.56 |
10:31 ET | 32594 | 6.58 |
10:33 ET | 34879 | 6.6 |
10:36 ET | 4298 | 6.6 |
10:38 ET | 6000 | 6.6 |
10:40 ET | 906 | 6.59 |
10:42 ET | 14007 | 6.57 |
10:44 ET | 3743 | 6.5599 |
10:45 ET | 2500 | 6.6 |
10:47 ET | 300 | 6.6 |
10:49 ET | 11366 | 6.59 |
10:51 ET | 7832 | 6.565 |
10:54 ET | 100 | 6.56 |
10:56 ET | 2189 | 6.55 |
10:58 ET | 1527 | 6.575 |
11:00 ET | 4297 | 6.59 |
11:02 ET | 1692 | 6.56 |
11:03 ET | 2726 | 6.57 |
11:05 ET | 4979 | 6.57 |
11:07 ET | 700 | 6.58 |
11:09 ET | 2935 | 6.59 |
11:12 ET | 7810 | 6.6196 |
11:14 ET | 300 | 6.61 |
11:16 ET | 2136 | 6.62 |
11:18 ET | 6854 | 6.65 |
11:20 ET | 700 | 6.6452 |
11:21 ET | 3200 | 6.65 |
11:23 ET | 100 | 6.65 |
11:25 ET | 5702 | 6.659 |
11:27 ET | 7947 | 6.66 |
11:30 ET | 12389 | 6.705 |
11:32 ET | 800 | 6.6901 |
11:34 ET | 1900 | 6.695 |
11:36 ET | 4600 | 6.725 |
11:38 ET | 600 | 6.75 |
11:39 ET | 3450 | 6.75 |
11:41 ET | 31836 | 6.8543 |
11:43 ET | 3826 | 6.8 |
11:45 ET | 7385 | 6.82 |
11:48 ET | 3436 | 6.7714 |
11:50 ET | 700 | 6.76 |
11:52 ET | 2400 | 6.78 |
11:54 ET | 1200 | 6.77 |
11:56 ET | 600 | 6.76 |
11:57 ET | 300 | 6.75 |
11:59 ET | 4400 | 6.758 |
12:01 ET | 2800 | 6.75 |
12:03 ET | 1850 | 6.76 |
12:06 ET | 4649 | 6.7514 |
12:08 ET | 10232 | 6.73 |
12:10 ET | 21221 | 6.675 |
12:12 ET | 12744 | 6.73 |
12:14 ET | 12698 | 6.75 |
12:15 ET | 15851 | 6.81 |
12:17 ET | 8480 | 6.795 |
12:19 ET | 17691 | 6.831 |
12:21 ET | 8815 | 6.83 |
12:24 ET | 2966 | 6.82 |
12:26 ET | 100 | 6.81 |
12:28 ET | 7539 | 6.82 |
12:30 ET | 4503 | 6.83 |
12:32 ET | 1301 | 6.83 |
12:33 ET | 8192 | 6.8106 |
12:35 ET | 300 | 6.8105 |
12:37 ET | 5973 | 6.84 |
12:39 ET | 11002 | 6.86 |
12:42 ET | 21525 | 6.87 |
12:44 ET | 11353 | 6.875 |
12:46 ET | 26390 | 6.91 |
12:48 ET | 7639 | 6.8325 |
12:50 ET | 1200 | 6.825 |
12:51 ET | 713 | 6.835 |
12:53 ET | 15660 | 6.919 |
12:55 ET | 19744 | 6.92 |
12:57 ET | 11514 | 6.85 |
01:00 ET | 3333 | 6.84 |
01:02 ET | 8523 | 6.84 |
01:04 ET | 6900 | 6.88 |
01:06 ET | 8891 | 6.855 |
01:08 ET | 1250 | 6.885 |
01:09 ET | 1688 | 6.905 |
01:11 ET | 8299 | 6.93 |
01:13 ET | 6341 | 6.89 |
01:15 ET | 10064 | 6.84 |
01:18 ET | 2500 | 6.83 |
01:20 ET | 5823 | 6.78 |
01:22 ET | 10689 | 6.73 |
01:26 ET | 2600 | 6.72 |
01:27 ET | 1748 | 6.72 |
01:31 ET | 2953 | 6.765 |
01:33 ET | 1835 | 6.76 |
01:36 ET | 897 | 6.77 |
01:38 ET | 35061 | 6.845 |
01:40 ET | 7270 | 6.8 |
01:42 ET | 5231 | 6.78 |
01:44 ET | 1200 | 6.775 |
01:45 ET | 8931 | 6.83 |
01:47 ET | 55282 | 6.95 |
01:49 ET | 5663 | 6.88 |
01:51 ET | 8611 | 6.85 |
01:54 ET | 6590 | 6.79 |
01:56 ET | 4618 | 6.77 |
01:58 ET | 1720 | 6.77 |
02:02 ET | 8794 | 6.84 |
02:03 ET | 5559 | 6.87 |
02:05 ET | 14082 | 6.86 |
02:07 ET | 15700 | 6.83 |
02:09 ET | 2650 | 6.7808 |
02:12 ET | 7758 | 6.78 |
02:14 ET | 2074 | 6.78 |
02:16 ET | 1704 | 6.8 |
02:18 ET | 4969 | 6.85 |
02:20 ET | 5199 | 6.84 |
02:21 ET | 4920 | 6.87 |
02:23 ET | 11095 | 6.86 |
02:25 ET | 3042 | 6.835 |
02:27 ET | 29719 | 6.86 |
02:30 ET | 8096 | 6.88 |
02:32 ET | 20948 | 6.895 |
02:34 ET | 8254 | 6.845 |
02:36 ET | 2168 | 6.82 |
02:38 ET | 4327 | 6.845 |
02:39 ET | 11289 | 6.825 |
02:41 ET | 3287 | 6.87 |
02:43 ET | 3567 | 6.85 |
02:45 ET | 5399 | 6.85 |
02:48 ET | 4600 | 6.83 |
02:50 ET | 7667 | 6.86 |
02:52 ET | 8808 | 6.87 |
02:54 ET | 8099 | 6.85 |
02:56 ET | 3156 | 6.84 |
02:57 ET | 4931 | 6.84 |
02:59 ET | 6578 | 6.87 |
03:01 ET | 2669 | 6.9 |
03:03 ET | 6912 | 6.91 |
03:06 ET | 14368 | 6.94 |
03:08 ET | 28963 | 6.94 |
03:10 ET | 4895 | 6.9 |
03:12 ET | 2807 | 6.95 |
03:14 ET | 3924 | 6.93 |
03:15 ET | 533 | 6.94 |
03:17 ET | 3749 | 6.92 |
03:19 ET | 973 | 6.93 |
03:21 ET | 6080 | 6.92 |
03:24 ET | 8167 | 6.9 |
03:26 ET | 3037 | 6.88 |
03:28 ET | 200 | 6.89 |
03:30 ET | 3189 | 6.905 |
03:32 ET | 6838 | 6.93 |
03:33 ET | 9168 | 6.9106 |
03:35 ET | 7022 | 6.915 |
03:37 ET | 9282 | 6.885 |
03:39 ET | 6644 | 6.87 |
03:42 ET | 1300 | 6.875 |
03:44 ET | 3086 | 6.86 |
03:46 ET | 1581 | 6.87 |
03:48 ET | 58074 | 6.955 |
03:50 ET | 24102 | 6.92 |
03:51 ET | 12193 | 6.885 |
03:53 ET | 98276 | 6.985 |
03:55 ET | 186602 | 7.005 |
03:57 ET | 45741 | 6.985 |
04:00 ET | 424363 | 7.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MorphoSys AG | 910.8M | 9.6x | --- |
MiMedx Group Inc | 929.8M | -323.0x | --- |
CareDx Inc | 534.5M | -5.9x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -4.9x | --- |
Kiniksa Pharmaceuticals Ltd | 1.2B | -165.9x | --- |
Immatics NV | 762.8M | -11.0x | --- |
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $910.8M |
---|---|
Revenue (TTM) | $283.8M |
Shares Outstanding | 136.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $0.73 |
Book Value | $1.25 |
P/E Ratio | 9.6x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | 8.2x |
Operating Margin | -90.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.